[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f0s2ncJmKalHq5W1mAY-IDMCXaMfmjOtdBHG23G8nNyM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":34,"phaseBuckets":84,"rows":91},"Third Affiliated Hospital, Sun Yat-Sen University",[4],128,false,28,5,104122,53,[13,16,19,22,25,27,30,32],{"name":14,"count":15},"Chronic Hepatitis B",12,{"name":17,"count":18},"Acute-On-Chronic Liver Failure",10,{"name":20,"count":21},"Hepatitis B",9,{"name":23,"count":24},"Hepatocellular Carcinoma",7,{"name":26,"count":24},"Hepatitis B, Chronic",{"name":28,"count":29},"Chronic Hepatitis b",6,{"name":31,"count":29},"Liver Failure",{"name":33,"count":9},"Chronic Hepatitis C",[35,40,45,50,55,59,64,69,74,79],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT02779465","Oral Vitamin D Treatment for the Prevention of Hepatocellular Carcinoma","2016-06","Vitamin D3",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT04231565","Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.","2024-06-01","Tenofovir alafenamide Fumarate",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT05991856","Multifaceted Comparison of Ultrasound-guided Ablation and Laparoscopic Adrenalectomy for Aldosterone-producing Adenoma","2024-10-01","Hypotensive Drugs",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT03920618","Three Types of Nucleotide\u002FNucleoside Analogues Treatment in HBV Related ACLF","2024-12-31","Entecavir",{"nctId":56,"briefTitle":57,"date":53,"intervention":58},"NCT02883647","Therapeutic Effects and Long-term Follow-up After Ending Nucleos(t)Ide Analogs Therapy in Chronic Hepatitis b","Entecavir or Tenofovir",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT04035837","The Clinical Cure Project of Chronic Hepatitis B in China","2025-12-31","pegylated interferon-alfa",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT06825572","MSC-EVs in Acute\u002F Acute-on-Chronic Liver Failure After Liver Transplantation","2026-03-30","MSC-EVs",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT06510114","A Randomized Clinical Trial of Intravenous Methylprednisolone With 2 Protocols in Patients With Graves Orbitopathy","2026-06","methylprednisolone",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT07353216","Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) Levels","2026-12-01","Ofatumumab",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT05182463","Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients","2026-12-13","Peginterferon Alfa-2B",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,116,138,161,219,251,280,298,316,344,378,405,423,441,459,483,509,527,594,647,674,707,730,753,776,797,821,845,872,927,964,990,1016,1034,1060,1085,1103,1127,1145,1170,1188,1206,1224,1242,1266,1291,1316,1334,1376,1402,1427,1445,1463,1481,1519,1545,1569,1587,1605,1623,1641,1659,1677,1699,1727,1753,1771,1789,1812,1835,1861,1879,1897,1921,1939,1957,1983,2005,2040,2062,2080,2107,2125,2150,2173,2202,2220,2244,2262,2285,2309],{"intervention":39,"totalTrials":93,"cells":94},1,{"EARLY_PHASE1":95,"PHASE1":98,"PHASE2":100,"PHASE3":102,"PHASE4":104,"NA":114},{"trials":96,"activeCount":97},[],0,{"trials":99,"activeCount":97},[],{"trials":101,"activeCount":97},[],{"trials":103,"activeCount":97},[],{"trials":105,"activeCount":93,"soonestReadout":38},[106],{"nctId":36,"briefTitle":37,"status":107,"phases":108,"primaryCompletion":38,"completion":109,"start":38,"enrollment":110,"conditions":111,"interventions":113},"NOT_YET_RECRUITING",[89],"2026-12",1500,[20,112],"Carcinoma, Hepatocellular",[39],{"trials":115,"activeCount":97},[],{"intervention":63,"totalTrials":93,"cells":117},{"EARLY_PHASE1":118,"PHASE1":120,"PHASE2":122,"PHASE3":124,"PHASE4":126,"NA":136},{"trials":119,"activeCount":97},[],{"trials":121,"activeCount":97},[],{"trials":123,"activeCount":97},[],{"trials":125,"activeCount":97},[],{"trials":127,"activeCount":93,"soonestReadout":62},[128],{"nctId":60,"briefTitle":61,"status":129,"phases":130,"primaryCompletion":62,"completion":131,"start":132,"enrollment":133,"conditions":134,"interventions":135},"ACTIVE_NOT_RECRUITING",[89],"2026-06-30","2018-05-16",30000,[26],[63],{"trials":137,"activeCount":97},[],{"intervention":139,"totalTrials":93,"cells":140},"Nucleoside Analogs",{"EARLY_PHASE1":141,"PHASE1":143,"PHASE2":145,"PHASE3":147,"PHASE4":149,"NA":159},{"trials":142,"activeCount":97},[],{"trials":144,"activeCount":97},[],{"trials":146,"activeCount":97},[],{"trials":148,"activeCount":97},[],{"trials":150,"activeCount":93,"soonestReadout":82},[151],{"nctId":80,"briefTitle":81,"status":152,"phases":153,"primaryCompletion":82,"completion":154,"start":155,"enrollment":156,"conditions":157,"interventions":158},"RECRUITING",[89],"2029-11-30","2022-01-08",5000,[26],[83,139],{"trials":160,"activeCount":97},[],{"intervention":162,"totalTrials":9,"cells":163},"Peginterferon Alfa-2b",{"EARLY_PHASE1":164,"PHASE1":166,"PHASE2":168,"PHASE3":170,"PHASE4":172,"NA":188},{"trials":165,"activeCount":97},[],{"trials":167,"activeCount":97},[],{"trials":169,"activeCount":97},[],{"trials":171,"activeCount":97},[],{"trials":173,"activeCount":93,"soonestReadout":82},[174,178],{"nctId":80,"briefTitle":81,"status":152,"phases":175,"primaryCompletion":82,"completion":154,"start":155,"enrollment":156,"conditions":176,"interventions":177},[89],[26],[83,139],{"nctId":179,"briefTitle":180,"status":181,"phases":182,"primaryCompletion":183,"completion":183,"start":184,"enrollment":185,"conditions":186,"interventions":187},"NCT02973646","Peginterferon Alfa-2b Treatment in HBeAg(+) Chronic Hepatitis b Patients Based on Interferon Gene Mutation and Receptor Detection","UNKNOWN",[89],"2018-12","2016-01",100,[28],[58,83],{"trials":189,"activeCount":97},[190,203,212],{"nctId":191,"briefTitle":192,"status":181,"phases":193,"primaryCompletion":194,"completion":195,"start":196,"enrollment":197,"conditions":198,"interventions":200},"NCT03919565","Optimized Treatment of Peginterferon Alfa 2a\u002F2b in Anti-virus Treatment Naive Patients With HBV Related Liver Fibrosis",[90],"2021-10-31","2021-12-31","2019-02-01",120,[20,199],"Liver Fibrosis",[201,202,162],"Tenofovir Disoproxil Fumarate","Peginterferon Alfa-2a",{"nctId":204,"briefTitle":205,"status":181,"phases":206,"primaryCompletion":207,"start":208,"enrollment":197,"conditions":209,"interventions":210},"NCT02605252","New Strategy Study of Functional Cure of Chronic Hepatitis B",[90],"2017-09","2016-03",[26],[211],"Peginterferon alfa-2b",{"nctId":213,"briefTitle":214,"status":181,"phases":215,"primaryCompletion":216,"completion":195,"start":196,"enrollment":185,"conditions":217,"interventions":218},"NCT03920605","Optimized Treatment of Peginterferon Alfa 2a\u002F2b in Treatment Experienced Patients With HBV Related Liver Fibrosis",[90],"2021-10-30",[20,199],[201,202,162],{"intervention":73,"totalTrials":220,"cells":221},2,{"EARLY_PHASE1":222,"PHASE1":224,"PHASE2":226,"PHASE3":228,"PHASE4":230,"NA":239},{"trials":223,"activeCount":97},[],{"trials":225,"activeCount":97},[],{"trials":227,"activeCount":97},[],{"trials":229,"activeCount":97},[],{"trials":231,"activeCount":93,"soonestReadout":72},[232],{"nctId":70,"briefTitle":71,"status":107,"phases":233,"primaryCompletion":72,"completion":109,"start":234,"enrollment":235,"conditions":236,"interventions":238},[89],"2024-07",150,[237],"Graves Ophthalmopathy",[73,73],{"trials":240,"activeCount":97},[241],{"nctId":242,"briefTitle":243,"status":181,"phases":244,"primaryCompletion":245,"completion":246,"start":247,"enrollment":197,"conditions":248,"interventions":250},"NCT01627236","Efficacy of Short-term Immunosuppressive Therapy and Anti-allergenic Therapy in Severe Acute Exacerbation of Chronic Hepatitis B",[90],"2014-08","2014-11","2012-12",[249],"Severe Acute Exacerbation of Chronic Hepatitis B",[73],{"intervention":252,"totalTrials":93,"cells":253},"Hepatic Arterial Infusion Chemotherapy",{"EARLY_PHASE1":254,"PHASE1":256,"PHASE2":258,"PHASE3":274,"PHASE4":276,"NA":278},{"trials":255,"activeCount":97},[],{"trials":257,"activeCount":97},[],{"trials":259,"activeCount":93,"soonestReadout":264},[260],{"nctId":261,"briefTitle":262,"status":107,"phases":263,"primaryCompletion":264,"completion":264,"start":265,"enrollment":266,"conditions":267,"interventions":271},"NCT07543783","Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial",[87],"2029-08-31","2026-04-10",38,[268,269,270],"Adebrelimab (SHR-1316)","Bevacizumab","Hepatocellular Carcinoma (HCC)",[252,272,273],"Adebrelimab","Low-dose Bevacizumab",{"trials":275,"activeCount":97},[],{"trials":277,"activeCount":97},[],{"trials":279,"activeCount":97},[],{"intervention":272,"totalTrials":93,"cells":281},{"EARLY_PHASE1":282,"PHASE1":284,"PHASE2":286,"PHASE3":292,"PHASE4":294,"NA":296},{"trials":283,"activeCount":97},[],{"trials":285,"activeCount":97},[],{"trials":287,"activeCount":93,"soonestReadout":264},[288],{"nctId":261,"briefTitle":262,"status":107,"phases":289,"primaryCompletion":264,"completion":264,"start":265,"enrollment":266,"conditions":290,"interventions":291},[87],[268,269,270],[252,272,273],{"trials":293,"activeCount":97},[],{"trials":295,"activeCount":97},[],{"trials":297,"activeCount":97},[],{"intervention":273,"totalTrials":93,"cells":299},{"EARLY_PHASE1":300,"PHASE1":302,"PHASE2":304,"PHASE3":310,"PHASE4":312,"NA":314},{"trials":301,"activeCount":97},[],{"trials":303,"activeCount":97},[],{"trials":305,"activeCount":93,"soonestReadout":264},[306],{"nctId":261,"briefTitle":262,"status":107,"phases":307,"primaryCompletion":264,"completion":264,"start":265,"enrollment":266,"conditions":308,"interventions":309},[87],[268,269,270],[252,272,273],{"trials":311,"activeCount":97},[],{"trials":313,"activeCount":97},[],{"trials":315,"activeCount":97},[],{"intervention":317,"totalTrials":93,"cells":318},"Low-dose Gemcitabine and Cisplatin Chemotherapy plus PD-1\u002FPD-L1Antibody",{"EARLY_PHASE1":319,"PHASE1":321,"PHASE2":323,"PHASE3":338,"PHASE4":340,"NA":342},{"trials":320,"activeCount":97},[],{"trials":322,"activeCount":97},[],{"trials":324,"activeCount":93,"soonestReadout":329},[325],{"nctId":326,"briefTitle":327,"status":107,"phases":328,"primaryCompletion":329,"completion":330,"start":331,"enrollment":332,"conditions":333,"interventions":337},"NCT06567600","Low-dose Gemcitabine and Cisplatin and PD-1\u002FPD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma",[87],"2027-12-31","2028-12-31","2024-09-01",43,[334,335,336],"Intrahepatic Cholangiocarcinoma","Chemotherapy Effect","Immunotherapy",[317],{"trials":339,"activeCount":97},[],{"trials":341,"activeCount":97},[],{"trials":343,"activeCount":97},[],{"intervention":68,"totalTrials":220,"cells":345},{"EARLY_PHASE1":346,"PHASE1":348,"PHASE2":359,"PHASE3":372,"PHASE4":374,"NA":376},{"trials":347,"activeCount":97},[],{"trials":349,"activeCount":93,"soonestReadout":67},[350],{"nctId":65,"briefTitle":66,"status":107,"phases":351,"primaryCompletion":67,"completion":352,"start":353,"enrollment":354,"conditions":355,"interventions":358},[86],"2026-09-30","2025-04-01",30,[31,356,357],"Mesenchymal Stem Cell","Extracellular Vesicles",[68],{"trials":360,"activeCount":97},[361],{"nctId":362,"briefTitle":363,"status":364,"phases":365,"primaryCompletion":366,"completion":367,"start":368,"enrollment":97,"conditions":369,"interventions":371},"NCT05940610","The Safety and Efficacy of MSC-EVs in Acute\u002FAcute-on-Chronic Liver Failure","WITHDRAWN",[86,87],"2024-09-30","2025-10-01","2023-09-01",[17,370],"Acute Liver Failure",[68],{"trials":373,"activeCount":97},[],{"trials":375,"activeCount":97},[],{"trials":377,"activeCount":97},[],{"intervention":379,"totalTrials":93,"cells":380},"Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification（4 hours）",{"EARLY_PHASE1":381,"PHASE1":383,"PHASE2":397,"PHASE3":399,"PHASE4":401,"NA":403},{"trials":382,"activeCount":97},[],{"trials":384,"activeCount":93,"soonestReadout":389},[385],{"nctId":386,"briefTitle":387,"status":129,"phases":388,"primaryCompletion":389,"completion":389,"start":390,"enrollment":391,"conditions":392,"interventions":393},"NCT06996392","Phase I Trial of QH-1A Hybrid Bio-Artificial Liver With Ex Vivo Blood-Purifying MSCs in Acute-on-Chronic Liver Failure",[86],"2026-12-31","2025-05-07",15,[17],[379,394,395,396],"Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification（6 hours）","Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification（8 hours）","Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification（Multiple-treatment）",{"trials":398,"activeCount":97},[],{"trials":400,"activeCount":97},[],{"trials":402,"activeCount":97},[],{"trials":404,"activeCount":97},[],{"intervention":394,"totalTrials":93,"cells":406},{"EARLY_PHASE1":407,"PHASE1":409,"PHASE2":415,"PHASE3":417,"PHASE4":419,"NA":421},{"trials":408,"activeCount":97},[],{"trials":410,"activeCount":93,"soonestReadout":389},[411],{"nctId":386,"briefTitle":387,"status":129,"phases":412,"primaryCompletion":389,"completion":389,"start":390,"enrollment":391,"conditions":413,"interventions":414},[86],[17],[379,394,395,396],{"trials":416,"activeCount":97},[],{"trials":418,"activeCount":97},[],{"trials":420,"activeCount":97},[],{"trials":422,"activeCount":97},[],{"intervention":395,"totalTrials":93,"cells":424},{"EARLY_PHASE1":425,"PHASE1":427,"PHASE2":433,"PHASE3":435,"PHASE4":437,"NA":439},{"trials":426,"activeCount":97},[],{"trials":428,"activeCount":93,"soonestReadout":389},[429],{"nctId":386,"briefTitle":387,"status":129,"phases":430,"primaryCompletion":389,"completion":389,"start":390,"enrollment":391,"conditions":431,"interventions":432},[86],[17],[379,394,395,396],{"trials":434,"activeCount":97},[],{"trials":436,"activeCount":97},[],{"trials":438,"activeCount":97},[],{"trials":440,"activeCount":97},[],{"intervention":396,"totalTrials":93,"cells":442},{"EARLY_PHASE1":443,"PHASE1":445,"PHASE2":451,"PHASE3":453,"PHASE4":455,"NA":457},{"trials":444,"activeCount":97},[],{"trials":446,"activeCount":93,"soonestReadout":389},[447],{"nctId":386,"briefTitle":387,"status":129,"phases":448,"primaryCompletion":389,"completion":389,"start":390,"enrollment":391,"conditions":449,"interventions":450},[86],[17],[379,394,395,396],{"trials":452,"activeCount":97},[],{"trials":454,"activeCount":97},[],{"trials":456,"activeCount":97},[],{"trials":458,"activeCount":97},[],{"intervention":460,"totalTrials":93,"cells":461},"Concentrated Growth Factors",{"EARLY_PHASE1":462,"PHASE1":473,"PHASE2":475,"PHASE3":477,"PHASE4":479,"NA":481},{"trials":463,"activeCount":93,"soonestReadout":468},[464],{"nctId":465,"briefTitle":466,"status":107,"phases":467,"primaryCompletion":468,"completion":468,"start":469,"enrollment":18,"conditions":470,"interventions":472},"NCT07253233","Treatment of Spinal Cord Injury Using Autologous Concentrated Growth Factors",[85],"2027-07-31","2025-12-01",[471],"Spinal Cord Injury",[460],{"trials":474,"activeCount":97},[],{"trials":476,"activeCount":97},[],{"trials":478,"activeCount":97},[],{"trials":480,"activeCount":97},[],{"trials":482,"activeCount":97},[],{"intervention":484,"totalTrials":93,"cells":485},"exosome",{"EARLY_PHASE1":486,"PHASE1":499,"PHASE2":501,"PHASE3":503,"PHASE4":505,"NA":507},{"trials":487,"activeCount":93,"soonestReadout":492},[488],{"nctId":489,"briefTitle":490,"status":129,"phases":491,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":495,"interventions":497},"NCT07409259","PT-MSCs Exosome Injection in the Treatment of Chronic-to-acute Liver Failure",[85],"2027-08-31","2026-01-01",20,[496],"Acute-on-Chronic Liver Failure (ACLF)",[484,498],"standard comprehensive internal medical treatment,",{"trials":500,"activeCount":97},[],{"trials":502,"activeCount":97},[],{"trials":504,"activeCount":97},[],{"trials":506,"activeCount":97},[],{"trials":508,"activeCount":97},[],{"intervention":498,"totalTrials":93,"cells":510},{"EARLY_PHASE1":511,"PHASE1":517,"PHASE2":519,"PHASE3":521,"PHASE4":523,"NA":525},{"trials":512,"activeCount":93,"soonestReadout":492},[513],{"nctId":489,"briefTitle":490,"status":129,"phases":514,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":515,"interventions":516},[85],[496],[484,498],{"trials":518,"activeCount":97},[],{"trials":520,"activeCount":97},[],{"trials":522,"activeCount":97},[],{"trials":524,"activeCount":97},[],{"trials":526,"activeCount":97},[],{"intervention":201,"totalTrials":24,"cells":528},{"EARLY_PHASE1":529,"PHASE1":531,"PHASE2":533,"PHASE3":535,"PHASE4":537,"NA":549},{"trials":530,"activeCount":97},[],{"trials":532,"activeCount":97},[],{"trials":534,"activeCount":97},[],{"trials":536,"activeCount":97},[],{"trials":538,"activeCount":97},[539],{"nctId":540,"briefTitle":541,"status":181,"phases":542,"primaryCompletion":543,"completion":543,"start":544,"enrollment":545,"conditions":546,"interventions":547},"NCT04640129","HBsAg Seroclearance in Adults With HBV Related Liver Fibrosis After Receiving Combined Therapy of Peg-IFN and Tenofovir.",[89],"2025-11","2021-01-01",336,[199],[548,201],"PEG-Interferon Alfa, Tenofovir Disoproxil Fumarate",{"trials":550,"activeCount":93,"soonestReadout":53},[551,562,566,572,576,586],{"nctId":552,"briefTitle":553,"status":181,"phases":554,"primaryCompletion":555,"completion":556,"start":557,"enrollment":558,"conditions":559,"interventions":560},"NCT03957629","Optimized Treatment of Peginterferon Alfa 2a in Treatment Experienced Patients With HBV Related Liver Fibrosis",[90],"2021-07-30","2023-07-30","2019-11-06",186,[20,199],[201,561],"PEG-Interferon alfa 2a",{"nctId":191,"briefTitle":192,"status":181,"phases":563,"primaryCompletion":194,"completion":195,"start":196,"enrollment":197,"conditions":564,"interventions":565},[90],[20,199],[201,202,162],{"nctId":51,"briefTitle":52,"status":152,"phases":567,"primaryCompletion":53,"completion":53,"start":568,"enrollment":235,"conditions":569,"interventions":570},[90],"2019-02-21",[20,17],[54,201,571],"Tenofovir Alafenamide",{"nctId":213,"briefTitle":214,"status":181,"phases":573,"primaryCompletion":216,"completion":195,"start":196,"enrollment":185,"conditions":574,"interventions":575},[90],[20,199],[201,202,162],{"nctId":577,"briefTitle":578,"status":181,"phases":579,"primaryCompletion":580,"completion":580,"start":581,"enrollment":235,"conditions":582,"interventions":584},"NCT04196998","Three Types of Nucleotide\u002FNucleoside Analogues Therapy in Patients With Hepatitis b Virus Related Compensated Cirrhosis",[90],"2023-12","2019-01-01",[20,583],"Compensated Cirrhosis",[54,201,585],"Tenofovir alafenamide",{"nctId":587,"briefTitle":588,"status":181,"phases":589,"primaryCompletion":590,"completion":53,"start":581,"enrollment":591,"conditions":592,"interventions":593},"NCT04195074","Three Types of Nucleotide\u002FNucleoside Analogues Therapy in Patients With Chronic Hepatitis b",[90],"2023-12-31",300,[28],[54,201,571],{"intervention":54,"totalTrials":9,"cells":595},{"EARLY_PHASE1":596,"PHASE1":598,"PHASE2":600,"PHASE3":616,"PHASE4":631,"NA":633},{"trials":597,"activeCount":97},[],{"trials":599,"activeCount":97},[],{"trials":601,"activeCount":97},[602],{"nctId":603,"briefTitle":604,"status":181,"phases":605,"primaryCompletion":606,"completion":606,"start":607,"enrollment":608,"conditions":609,"interventions":610},"NCT02615639","A Clinical Trial on Hepatitis B Vaccine Activated-Dendritic Cells Combined With Anti-HBV Drugs in CHB",[86,87],"2018-11","2015-11",450,[14],[611,54,612,613,614,615],"HPDC-T cells & Entecavir","HPDC-T cells & IFN-a-2a","IFN-a-2a","HPDC-T cells & Telbivudine","Telbivudine",{"trials":617,"activeCount":97},[618],{"nctId":619,"briefTitle":620,"status":621,"phases":622,"primaryCompletion":623,"completion":624,"start":625,"enrollment":626,"conditions":627,"interventions":629},"NCT01892241","Efficacy and Safety of Peginterferon a-2a in Patients of Chronic Hepatitis B With Spontaneous Decline of HBV DNA","COMPLETED",[88],"2012-11","2013-02","2010-01",74,[628],"Antiviral Treatment of Chronic Hepatitis B",[630,54],"Pegasys",{"trials":632,"activeCount":97},[],{"trials":634,"activeCount":93,"soonestReadout":53},[635,639,643],{"nctId":51,"briefTitle":52,"status":152,"phases":636,"primaryCompletion":53,"completion":53,"start":568,"enrollment":235,"conditions":637,"interventions":638},[90],[20,17],[54,201,571],{"nctId":577,"briefTitle":578,"status":181,"phases":640,"primaryCompletion":580,"completion":580,"start":581,"enrollment":235,"conditions":641,"interventions":642},[90],[20,583],[54,201,585],{"nctId":587,"briefTitle":588,"status":181,"phases":644,"primaryCompletion":590,"completion":53,"start":581,"enrollment":591,"conditions":645,"interventions":646},[90],[28],[54,201,571],{"intervention":571,"totalTrials":648,"cells":649},3,{"EARLY_PHASE1":650,"PHASE1":652,"PHASE2":654,"PHASE3":656,"PHASE4":658,"NA":660},{"trials":651,"activeCount":97},[],{"trials":653,"activeCount":97},[],{"trials":655,"activeCount":97},[],{"trials":657,"activeCount":97},[],{"trials":659,"activeCount":97},[],{"trials":661,"activeCount":93,"soonestReadout":53},[662,666,670],{"nctId":51,"briefTitle":52,"status":152,"phases":663,"primaryCompletion":53,"completion":53,"start":568,"enrollment":235,"conditions":664,"interventions":665},[90],[20,17],[54,201,571],{"nctId":577,"briefTitle":578,"status":181,"phases":667,"primaryCompletion":580,"completion":580,"start":581,"enrollment":235,"conditions":668,"interventions":669},[90],[20,583],[54,201,585],{"nctId":587,"briefTitle":588,"status":181,"phases":671,"primaryCompletion":590,"completion":53,"start":581,"enrollment":591,"conditions":672,"interventions":673},[90],[28],[54,201,571],{"intervention":44,"totalTrials":220,"cells":675},{"EARLY_PHASE1":676,"PHASE1":678,"PHASE2":680,"PHASE3":682,"PHASE4":684,"NA":686},{"trials":677,"activeCount":97},[],{"trials":679,"activeCount":97},[],{"trials":681,"activeCount":97},[],{"trials":683,"activeCount":97},[],{"trials":685,"activeCount":97},[],{"trials":687,"activeCount":93,"soonestReadout":43},[688,696],{"nctId":41,"briefTitle":42,"status":152,"phases":689,"primaryCompletion":43,"completion":690,"start":691,"enrollment":692,"conditions":693,"interventions":695},[90],"2027-07-01","2020-06-04",200,[694],"Hepatitis B Virus",[44],{"nctId":697,"briefTitle":698,"status":181,"phases":699,"primaryCompletion":194,"completion":700,"start":701,"enrollment":692,"conditions":702,"interventions":704},"NCT04501224","The Efficacy and Safety of TAF vs Other NAs in Patients With LVL",[90],"2024-04-30","2020-08-03",[28,703],"Cirrhosis Due to Hepatitis B",[705,706],"Tenofovir alafenamide fumarate","Entecavir or Tenofovir disoproxil fumarate",{"intervention":58,"totalTrials":220,"cells":708},{"EARLY_PHASE1":709,"PHASE1":711,"PHASE2":713,"PHASE3":715,"PHASE4":717,"NA":723},{"trials":710,"activeCount":97},[],{"trials":712,"activeCount":97},[],{"trials":714,"activeCount":97},[],{"trials":716,"activeCount":97},[],{"trials":718,"activeCount":97},[719],{"nctId":179,"briefTitle":180,"status":181,"phases":720,"primaryCompletion":183,"completion":183,"start":184,"enrollment":185,"conditions":721,"interventions":722},[89],[28],[58,83],{"trials":724,"activeCount":93,"soonestReadout":53},[725],{"nctId":56,"briefTitle":57,"status":152,"phases":726,"primaryCompletion":53,"completion":53,"start":727,"enrollment":185,"conditions":728,"interventions":729},[],"2014-01-01",[28],[58],{"intervention":731,"totalTrials":93,"cells":732},"bevacizumab and atezolizumab",{"EARLY_PHASE1":733,"PHASE1":735,"PHASE2":737,"PHASE3":739,"PHASE4":741,"NA":743},{"trials":734,"activeCount":97},[],{"trials":736,"activeCount":97},[],{"trials":738,"activeCount":97},[],{"trials":740,"activeCount":97},[],{"trials":742,"activeCount":97},[],{"trials":744,"activeCount":93,"soonestReadout":330},[745],{"nctId":746,"briefTitle":747,"status":107,"phases":748,"primaryCompletion":330,"completion":749,"start":493,"enrollment":354,"conditions":750,"interventions":752},"NCT07281664","Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma",[90],"2029-12-31",[23,751],"Transarterial Chemoembolization",[731],{"intervention":49,"totalTrials":93,"cells":754},{"EARLY_PHASE1":755,"PHASE1":757,"PHASE2":759,"PHASE3":761,"PHASE4":763,"NA":765},{"trials":756,"activeCount":97},[],{"trials":758,"activeCount":97},[],{"trials":760,"activeCount":97},[],{"trials":762,"activeCount":97},[],{"trials":764,"activeCount":97},[],{"trials":766,"activeCount":93,"soonestReadout":48},[767],{"nctId":46,"briefTitle":47,"status":152,"phases":768,"primaryCompletion":48,"completion":769,"start":770,"enrollment":771,"conditions":772,"interventions":775},[],"2030-12-01","2020-01-01",45,[773,774],"Aldosterone-producing Adenoma","Radiofrequency Ablation",[49],{"intervention":78,"totalTrials":93,"cells":777},{"EARLY_PHASE1":778,"PHASE1":780,"PHASE2":782,"PHASE3":784,"PHASE4":786,"NA":788},{"trials":779,"activeCount":97},[],{"trials":781,"activeCount":97},[],{"trials":783,"activeCount":97},[],{"trials":785,"activeCount":97},[],{"trials":787,"activeCount":97},[],{"trials":789,"activeCount":93,"soonestReadout":77},[790],{"nctId":75,"briefTitle":76,"status":152,"phases":791,"primaryCompletion":77,"completion":77,"start":792,"enrollment":793,"conditions":794,"interventions":796},[],"2023-12-01",80,[795],"Multiple Sclerosis",[78],{"intervention":798,"totalTrials":93,"cells":799},"TACE-HAIC + Atezolizumab + Low-dose Bevacizumab",{"EARLY_PHASE1":800,"PHASE1":802,"PHASE2":804,"PHASE3":806,"PHASE4":808,"NA":810},{"trials":801,"activeCount":97},[],{"trials":803,"activeCount":97},[],{"trials":805,"activeCount":97},[],{"trials":807,"activeCount":97},[],{"trials":809,"activeCount":97},[],{"trials":811,"activeCount":93,"soonestReadout":816},[812],{"nctId":813,"briefTitle":814,"status":107,"phases":815,"primaryCompletion":816,"completion":264,"start":817,"enrollment":266,"conditions":818,"interventions":820},"NCT07543510","Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma",[90],"2028-08-31","2026-05-01",[23,819,751],"Atezolizumab Plus Bevacizumab",[798],{"intervention":822,"totalTrials":93,"cells":823},"intravenous methylprednisolone",{"EARLY_PHASE1":824,"PHASE1":826,"PHASE2":828,"PHASE3":830,"PHASE4":832,"NA":834},{"trials":825,"activeCount":97},[],{"trials":827,"activeCount":97},[],{"trials":829,"activeCount":97},[],{"trials":831,"activeCount":97},[],{"trials":833,"activeCount":97},[],{"trials":835,"activeCount":93,"soonestReadout":389},[836],{"nctId":837,"briefTitle":838,"status":152,"phases":839,"primaryCompletion":389,"completion":389,"start":840,"enrollment":841,"conditions":842,"interventions":844},"NCT06763848","Protein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum Disorder",[90],"2025-04-25",144,[843],"Neuromyelitis Optica Spectrum Disorders",[822],{"intervention":846,"totalTrials":93,"cells":847},"Atezolizumab plus Bevacizumab",{"EARLY_PHASE1":848,"PHASE1":850,"PHASE2":852,"PHASE3":854,"PHASE4":856,"NA":858},{"trials":849,"activeCount":97},[],{"trials":851,"activeCount":97},[],{"trials":853,"activeCount":97},[],{"trials":855,"activeCount":97},[],{"trials":857,"activeCount":97},[],{"trials":859,"activeCount":93,"soonestReadout":864},[860],{"nctId":861,"briefTitle":862,"status":152,"phases":863,"primaryCompletion":864,"completion":865,"start":866,"enrollment":867,"conditions":868,"interventions":871},"NCT05984511","TACE Plus Atezolizumab\u002FBevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT",[90],"2028-08-01","2029-08-01","2023-08-30",234,[23,869,870],"Hepatic Portal Vein Tumor Invasion","Tumor Thrombus",[846],{"intervention":873,"totalTrials":9,"cells":874},"peginterferon alfa",{"EARLY_PHASE1":875,"PHASE1":877,"PHASE2":879,"PHASE3":881,"PHASE4":883,"NA":925},{"trials":876,"activeCount":97},[],{"trials":878,"activeCount":97},[],{"trials":880,"activeCount":97},[],{"trials":882,"activeCount":97},[],{"trials":884,"activeCount":97},[885,893,901,910,917],{"nctId":886,"briefTitle":887,"status":181,"phases":888,"primaryCompletion":889,"completion":889,"start":890,"enrollment":692,"conditions":891,"interventions":892},"NCT02908763","HBsAg Loss\u002FSeroconversion in Low Replicative Chronic Hepatitis B Virus(HBV) Infection Patients",[89],"2019-09","2016-08",[14],[873],{"nctId":894,"briefTitle":895,"status":181,"phases":896,"primaryCompletion":897,"completion":897,"start":38,"enrollment":692,"conditions":898,"interventions":899},"NCT02838810","The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg",[89],"2019-12",[14],[873,900],"Nucleoside analogues",{"nctId":902,"briefTitle":903,"status":181,"phases":904,"primaryCompletion":905,"completion":905,"start":581,"enrollment":692,"conditions":906,"interventions":907},"NCT03801538","The Optimizing Treatment of Peginterferon Alpha in Chronic Hepatitis B Patients With Low Level HBsAg",[89],"2020-12",[14],[908,909],"Peginterferon Alfa","Nucleoside Analog",{"nctId":911,"briefTitle":912,"status":181,"phases":913,"primaryCompletion":914,"completion":914,"start":890,"enrollment":692,"conditions":915,"interventions":916},"NCT02893124","The Optimizing Treatment of Peginterferon (PEG IFN) Alpha in Chronic Hepatitis B Virus Patients With Low Level HBsAg",[89],"2019-08",[14],[873],{"nctId":918,"briefTitle":895,"status":181,"phases":919,"primaryCompletion":920,"completion":920,"start":921,"enrollment":692,"conditions":922,"interventions":923},"NCT02745704",[89],"2019-04","2016-04",[14],[924],"Peginterferon alfa",{"trials":926,"activeCount":97},[],{"intervention":928,"totalTrials":220,"cells":929},"Metformin",{"EARLY_PHASE1":930,"PHASE1":945,"PHASE2":947,"PHASE3":949,"PHASE4":951,"NA":962},{"trials":931,"activeCount":97},[932],{"nctId":933,"briefTitle":934,"status":181,"phases":935,"primaryCompletion":936,"completion":937,"start":938,"enrollment":939,"conditions":940,"interventions":942},"NCT02587741","Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens",[85],"2023-07","2025-07","2015-07",600,[941],"Diabetic Retinopathy",[928,943,944],"Lantus","Novomix30",{"trials":946,"activeCount":97},[],{"trials":948,"activeCount":97},[],{"trials":950,"activeCount":97},[],{"trials":952,"activeCount":97},[953],{"nctId":954,"briefTitle":955,"status":621,"phases":956,"primaryCompletion":957,"completion":957,"start":38,"enrollment":354,"conditions":958,"interventions":960},"NCT02765347","The Effects of Metformin on Glycemic Control and Insulin Sensitivity in Adolescents With T1DM",[89],"2018-01",[959],"Diabetes Mellitus, Type 1",[928,961],"Insulin",{"trials":963,"activeCount":97},[],{"intervention":965,"totalTrials":93,"cells":966},"Compound Lidocaine Cream",{"EARLY_PHASE1":967,"PHASE1":969,"PHASE2":971,"PHASE3":973,"PHASE4":975,"NA":988},{"trials":968,"activeCount":97},[],{"trials":970,"activeCount":97},[],{"trials":972,"activeCount":97},[],{"trials":974,"activeCount":97},[],{"trials":976,"activeCount":97},[977],{"nctId":978,"briefTitle":979,"status":181,"phases":980,"primaryCompletion":981,"completion":982,"start":983,"enrollment":984,"conditions":985,"interventions":987},"NCT02017392","A RCT of Compound Lidocaine Cream to Prevent Postoperative Agitation in Patients With Endotracheal Intubation for GA",[89],"2014-03","2014-04","2013-12",2000,[986],"Postoperative Agitation of Patients",[965],{"trials":989,"activeCount":97},[],{"intervention":991,"totalTrials":93,"cells":992},"Entecavir combined long-term low-dose HBIG group intramuscular",{"EARLY_PHASE1":993,"PHASE1":995,"PHASE2":997,"PHASE3":999,"PHASE4":1001,"NA":1014},{"trials":994,"activeCount":97},[],{"trials":996,"activeCount":97},[],{"trials":998,"activeCount":97},[],{"trials":1000,"activeCount":97},[],{"trials":1002,"activeCount":97},[1003],{"nctId":1004,"briefTitle":1005,"status":181,"phases":1006,"primaryCompletion":1007,"completion":1007,"start":1008,"enrollment":1009,"conditions":1010,"interventions":1012},"NCT02417207","Entecavir Combined Short-term Intravenous Hepatitis B Immune Globulin (HBIG) to Prevent Hepatitis B Recurrence After Liver Transplantation",[89],"2018-04","2015-04",60,[20,1011],"Liver Transplantation",[991,1013],"Entecavir combined HBIG group short-term high-dose intravenous",{"trials":1015,"activeCount":97},[],{"intervention":1013,"totalTrials":93,"cells":1017},{"EARLY_PHASE1":1018,"PHASE1":1020,"PHASE2":1022,"PHASE3":1024,"PHASE4":1026,"NA":1032},{"trials":1019,"activeCount":97},[],{"trials":1021,"activeCount":97},[],{"trials":1023,"activeCount":97},[],{"trials":1025,"activeCount":97},[],{"trials":1027,"activeCount":97},[1028],{"nctId":1004,"briefTitle":1005,"status":181,"phases":1029,"primaryCompletion":1007,"completion":1007,"start":1008,"enrollment":1009,"conditions":1030,"interventions":1031},[89],[20,1011],[991,1013],{"trials":1033,"activeCount":97},[],{"intervention":1035,"totalTrials":93,"cells":1036},"Folic acid",{"EARLY_PHASE1":1037,"PHASE1":1039,"PHASE2":1041,"PHASE3":1043,"PHASE4":1045,"NA":1058},{"trials":1038,"activeCount":97},[],{"trials":1040,"activeCount":97},[],{"trials":1042,"activeCount":97},[],{"trials":1044,"activeCount":97},[],{"trials":1046,"activeCount":97},[1047],{"nctId":1048,"briefTitle":1049,"status":181,"phases":1050,"primaryCompletion":1051,"completion":1051,"start":1052,"enrollment":1053,"conditions":1054,"interventions":1057},"NCT02444013","Folic Acid for Prevention of Contrast Induced Nephropathy",[89],"2017-05","2015-05",400,[1055,1056],"Kidney Diseases","Urologic Diseases",[1035],{"trials":1059,"activeCount":97},[],{"intervention":1061,"totalTrials":93,"cells":1062},"Telbivudine 600mg",{"EARLY_PHASE1":1063,"PHASE1":1065,"PHASE2":1067,"PHASE3":1069,"PHASE4":1071,"NA":1083},{"trials":1064,"activeCount":97},[],{"trials":1066,"activeCount":97},[],{"trials":1068,"activeCount":97},[],{"trials":1070,"activeCount":97},[],{"trials":1072,"activeCount":97},[1073],{"nctId":1074,"briefTitle":1075,"status":621,"phases":1076,"primaryCompletion":1077,"completion":1077,"start":1078,"enrollment":1079,"conditions":1080,"interventions":1081},"NCT03468907","The Safety of Anti-viral Therapy in Preventing HBV MTCT in Pregnant Women After Discontinuation",[89],"2017-12-31","2015-06-01",111,[26],[1061,1082],"Tenofovir disoproxil fumarate 300mg",{"trials":1084,"activeCount":97},[],{"intervention":1082,"totalTrials":93,"cells":1086},{"EARLY_PHASE1":1087,"PHASE1":1089,"PHASE2":1091,"PHASE3":1093,"PHASE4":1095,"NA":1101},{"trials":1088,"activeCount":97},[],{"trials":1090,"activeCount":97},[],{"trials":1092,"activeCount":97},[],{"trials":1094,"activeCount":97},[],{"trials":1096,"activeCount":97},[1097],{"nctId":1074,"briefTitle":1075,"status":621,"phases":1098,"primaryCompletion":1077,"completion":1077,"start":1078,"enrollment":1079,"conditions":1099,"interventions":1100},[89],[26],[1061,1082],{"trials":1102,"activeCount":97},[],{"intervention":1104,"totalTrials":93,"cells":1105},"Vitamin D",{"EARLY_PHASE1":1106,"PHASE1":1108,"PHASE2":1110,"PHASE3":1112,"PHASE4":1114,"NA":1125},{"trials":1107,"activeCount":97},[],{"trials":1109,"activeCount":97},[],{"trials":1111,"activeCount":97},[],{"trials":1113,"activeCount":97},[],{"trials":1115,"activeCount":97},[1116],{"nctId":1117,"briefTitle":1118,"status":621,"phases":1119,"primaryCompletion":1120,"completion":1120,"start":1121,"enrollment":1122,"conditions":1123,"interventions":1124},"NCT05753280","Effect of Serum Vitamin D Level on the Efficacy of Peg-interferon Treatment in CHB",[89],"2022-06-30","2018-12-01",90,[28],[1104],{"trials":1126,"activeCount":97},[],{"intervention":900,"totalTrials":93,"cells":1128},{"EARLY_PHASE1":1129,"PHASE1":1131,"PHASE2":1133,"PHASE3":1135,"PHASE4":1137,"NA":1143},{"trials":1130,"activeCount":97},[],{"trials":1132,"activeCount":97},[],{"trials":1134,"activeCount":97},[],{"trials":1136,"activeCount":97},[],{"trials":1138,"activeCount":97},[1139],{"nctId":894,"briefTitle":895,"status":181,"phases":1140,"primaryCompletion":897,"completion":897,"start":38,"enrollment":692,"conditions":1141,"interventions":1142},[89],[14],[873,900],{"trials":1144,"activeCount":97},[],{"intervention":1146,"totalTrials":93,"cells":1147},"insulin lispro",{"EARLY_PHASE1":1148,"PHASE1":1150,"PHASE2":1152,"PHASE3":1154,"PHASE4":1156,"NA":1168},{"trials":1149,"activeCount":97},[],{"trials":1151,"activeCount":97},[],{"trials":1153,"activeCount":97},[],{"trials":1155,"activeCount":97},[],{"trials":1157,"activeCount":97},[1158],{"nctId":1159,"briefTitle":1160,"status":181,"phases":1161,"primaryCompletion":890,"completion":1162,"start":938,"enrollment":1163,"conditions":1164,"interventions":1166},"NCT02526810","Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes",[89],"2016-09",70,[1165],"Diabetes Mellitus, Type 2",[1146,1167],"Insulin Glargine",{"trials":1169,"activeCount":97},[],{"intervention":1167,"totalTrials":93,"cells":1171},{"EARLY_PHASE1":1172,"PHASE1":1174,"PHASE2":1176,"PHASE3":1178,"PHASE4":1180,"NA":1186},{"trials":1173,"activeCount":97},[],{"trials":1175,"activeCount":97},[],{"trials":1177,"activeCount":97},[],{"trials":1179,"activeCount":97},[],{"trials":1181,"activeCount":97},[1182],{"nctId":1159,"briefTitle":1160,"status":181,"phases":1183,"primaryCompletion":890,"completion":1162,"start":938,"enrollment":1163,"conditions":1184,"interventions":1185},[89],[1165],[1146,1167],{"trials":1187,"activeCount":97},[],{"intervention":909,"totalTrials":93,"cells":1189},{"EARLY_PHASE1":1190,"PHASE1":1192,"PHASE2":1194,"PHASE3":1196,"PHASE4":1198,"NA":1204},{"trials":1191,"activeCount":97},[],{"trials":1193,"activeCount":97},[],{"trials":1195,"activeCount":97},[],{"trials":1197,"activeCount":97},[],{"trials":1199,"activeCount":97},[1200],{"nctId":902,"briefTitle":903,"status":181,"phases":1201,"primaryCompletion":905,"completion":905,"start":581,"enrollment":692,"conditions":1202,"interventions":1203},[89],[14],[908,909],{"trials":1205,"activeCount":97},[],{"intervention":548,"totalTrials":93,"cells":1207},{"EARLY_PHASE1":1208,"PHASE1":1210,"PHASE2":1212,"PHASE3":1214,"PHASE4":1216,"NA":1222},{"trials":1209,"activeCount":97},[],{"trials":1211,"activeCount":97},[],{"trials":1213,"activeCount":97},[],{"trials":1215,"activeCount":97},[],{"trials":1217,"activeCount":97},[1218],{"nctId":540,"briefTitle":541,"status":181,"phases":1219,"primaryCompletion":543,"completion":543,"start":544,"enrollment":545,"conditions":1220,"interventions":1221},[89],[199],[548,201],{"trials":1223,"activeCount":97},[],{"intervention":961,"totalTrials":93,"cells":1225},{"EARLY_PHASE1":1226,"PHASE1":1228,"PHASE2":1230,"PHASE3":1232,"PHASE4":1234,"NA":1240},{"trials":1227,"activeCount":97},[],{"trials":1229,"activeCount":97},[],{"trials":1231,"activeCount":97},[],{"trials":1233,"activeCount":97},[],{"trials":1235,"activeCount":97},[1236],{"nctId":954,"briefTitle":955,"status":621,"phases":1237,"primaryCompletion":957,"completion":957,"start":38,"enrollment":354,"conditions":1238,"interventions":1239},[89],[959],[928,961],{"trials":1241,"activeCount":97},[],{"intervention":1243,"totalTrials":93,"cells":1244},"Avatrombopag",{"EARLY_PHASE1":1245,"PHASE1":1247,"PHASE2":1249,"PHASE3":1251,"PHASE4":1253,"NA":1264},{"trials":1246,"activeCount":97},[],{"trials":1248,"activeCount":97},[],{"trials":1250,"activeCount":97},[],{"trials":1252,"activeCount":97},[],{"trials":1254,"activeCount":97},[1255],{"nctId":1256,"briefTitle":1257,"status":181,"phases":1258,"primaryCompletion":1259,"completion":700,"start":1260,"enrollment":1009,"conditions":1261,"interventions":1263},"NCT05382013","Efficacy and Safety of Avatrombopag for Treating TCP in HBV-ACLF Patients Receiving ALSS Treatment",[89],"2024-02-29","2022-04-27",[1262,26,17],"Thrombocytopenia",[1243],{"trials":1265,"activeCount":97},[],{"intervention":1267,"totalTrials":93,"cells":1268},"Telbivudine, Adefovir dipivoxil",{"EARLY_PHASE1":1269,"PHASE1":1271,"PHASE2":1273,"PHASE3":1275,"PHASE4":1277,"NA":1289},{"trials":1270,"activeCount":97},[],{"trials":1272,"activeCount":97},[],{"trials":1274,"activeCount":97},[],{"trials":1276,"activeCount":97},[],{"trials":1278,"activeCount":97},[1279],{"nctId":1280,"briefTitle":1281,"status":621,"phases":1282,"primaryCompletion":1283,"completion":1284,"start":1285,"enrollment":1286,"conditions":1287,"interventions":1288},"NCT01521975","A Two-year Study of Telbivudine in HBeAg Negative Hepatitis",[89],"2014-02-28","2014-05-30","2011-01-01",360,[26],[1267],{"trials":1290,"activeCount":97},[],{"intervention":1292,"totalTrials":93,"cells":1293},"Mycophenolate mofetil",{"EARLY_PHASE1":1294,"PHASE1":1296,"PHASE2":1298,"PHASE3":1300,"PHASE4":1302,"NA":1314},{"trials":1295,"activeCount":97},[],{"trials":1297,"activeCount":97},[],{"trials":1299,"activeCount":97},[],{"trials":1301,"activeCount":97},[],{"trials":1303,"activeCount":97},[1304],{"nctId":1305,"briefTitle":1306,"status":181,"phases":1307,"primaryCompletion":1308,"completion":1308,"start":184,"enrollment":185,"conditions":1309,"interventions":1312},"NCT02809079","Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients",[89],"2017-12",[843,1310,1311],"Mycophenolate Mofetil","Efficacy and Safety",[1292,1313],"Prednisone",{"trials":1315,"activeCount":97},[],{"intervention":1313,"totalTrials":93,"cells":1317},{"EARLY_PHASE1":1318,"PHASE1":1320,"PHASE2":1322,"PHASE3":1324,"PHASE4":1326,"NA":1332},{"trials":1319,"activeCount":97},[],{"trials":1321,"activeCount":97},[],{"trials":1323,"activeCount":97},[],{"trials":1325,"activeCount":97},[],{"trials":1327,"activeCount":97},[1328],{"nctId":1305,"briefTitle":1306,"status":181,"phases":1329,"primaryCompletion":1308,"completion":1308,"start":184,"enrollment":185,"conditions":1330,"interventions":1331},[89],[843,1310,1311],[1292,1313],{"trials":1333,"activeCount":97},[],{"intervention":1335,"totalTrials":648,"cells":1336},"Peginterferon alfa2a",{"EARLY_PHASE1":1337,"PHASE1":1339,"PHASE2":1341,"PHASE3":1343,"PHASE4":1372,"NA":1374},{"trials":1338,"activeCount":97},[],{"trials":1340,"activeCount":97},[],{"trials":1342,"activeCount":97},[],{"trials":1344,"activeCount":97},[1345,1354,1363],{"nctId":1346,"briefTitle":1347,"status":181,"phases":1348,"primaryCompletion":1349,"completion":245,"start":1350,"enrollment":692,"conditions":1351,"interventions":1352},"NCT01441804","A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for Patients With Genotype 1 Hepatitis C and IL28B CC Polymorphism",[88],"2014-05","2011-05",[33],[1335,1353,1335,1353],"Ribavirin",{"nctId":1355,"briefTitle":1356,"status":621,"phases":1357,"primaryCompletion":1358,"completion":1358,"start":1359,"enrollment":1360,"conditions":1361,"interventions":1362},"NCT01263860","A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-6 Patients",[88],"2014-06","2010-12",242,[33],[1335,1353,1335,1353],{"nctId":1364,"briefTitle":1365,"status":621,"phases":1366,"primaryCompletion":1358,"completion":1358,"start":1367,"enrollment":1368,"conditions":1369,"interventions":1370},"NCT01433887","Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic Hepatitis C Genotypes 1 Versus 2\u002F3 Versus 6",[88],"2011-11",535,[33],[1371,1353,1335,1353],"48-weeks course",{"trials":1373,"activeCount":97},[],{"trials":1375,"activeCount":97},[],{"intervention":1353,"totalTrials":648,"cells":1377},{"EARLY_PHASE1":1378,"PHASE1":1380,"PHASE2":1382,"PHASE3":1384,"PHASE4":1398,"NA":1400},{"trials":1379,"activeCount":97},[],{"trials":1381,"activeCount":97},[],{"trials":1383,"activeCount":97},[],{"trials":1385,"activeCount":97},[1386,1390,1394],{"nctId":1346,"briefTitle":1347,"status":181,"phases":1387,"primaryCompletion":1349,"completion":245,"start":1350,"enrollment":692,"conditions":1388,"interventions":1389},[88],[33],[1335,1353,1335,1353],{"nctId":1355,"briefTitle":1356,"status":621,"phases":1391,"primaryCompletion":1358,"completion":1358,"start":1359,"enrollment":1360,"conditions":1392,"interventions":1393},[88],[33],[1335,1353,1335,1353],{"nctId":1364,"briefTitle":1365,"status":621,"phases":1395,"primaryCompletion":1358,"completion":1358,"start":1367,"enrollment":1368,"conditions":1396,"interventions":1397},[88],[33],[1371,1353,1335,1353],{"trials":1399,"activeCount":97},[],{"trials":1401,"activeCount":97},[],{"intervention":1403,"totalTrials":93,"cells":1404},"Lenvatinib",{"EARLY_PHASE1":1405,"PHASE1":1407,"PHASE2":1409,"PHASE3":1411,"PHASE4":1423,"NA":1425},{"trials":1406,"activeCount":97},[],{"trials":1408,"activeCount":97},[],{"trials":1410,"activeCount":97},[],{"trials":1412,"activeCount":97},[1413],{"nctId":1414,"briefTitle":1415,"status":181,"phases":1416,"primaryCompletion":1417,"completion":1418,"start":1419,"enrollment":1122,"conditions":1420,"interventions":1421},"NCT05250843","TACE\u002FHAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC",[87,88],"2023-12-30","2024-12-30","2022-05-30",[23],[1403,1422],"Sintilimab",{"trials":1424,"activeCount":97},[],{"trials":1426,"activeCount":97},[],{"intervention":1422,"totalTrials":93,"cells":1428},{"EARLY_PHASE1":1429,"PHASE1":1431,"PHASE2":1433,"PHASE3":1435,"PHASE4":1441,"NA":1443},{"trials":1430,"activeCount":97},[],{"trials":1432,"activeCount":97},[],{"trials":1434,"activeCount":97},[],{"trials":1436,"activeCount":97},[1437],{"nctId":1414,"briefTitle":1415,"status":181,"phases":1438,"primaryCompletion":1417,"completion":1418,"start":1419,"enrollment":1122,"conditions":1439,"interventions":1440},[87,88],[23],[1403,1422],{"trials":1442,"activeCount":97},[],{"trials":1444,"activeCount":97},[],{"intervention":630,"totalTrials":93,"cells":1446},{"EARLY_PHASE1":1447,"PHASE1":1449,"PHASE2":1451,"PHASE3":1453,"PHASE4":1459,"NA":1461},{"trials":1448,"activeCount":97},[],{"trials":1450,"activeCount":97},[],{"trials":1452,"activeCount":97},[],{"trials":1454,"activeCount":97},[1455],{"nctId":619,"briefTitle":620,"status":621,"phases":1456,"primaryCompletion":623,"completion":624,"start":625,"enrollment":626,"conditions":1457,"interventions":1458},[88],[628],[630,54],{"trials":1460,"activeCount":97},[],{"trials":1462,"activeCount":97},[],{"intervention":1371,"totalTrials":93,"cells":1464},{"EARLY_PHASE1":1465,"PHASE1":1467,"PHASE2":1469,"PHASE3":1471,"PHASE4":1477,"NA":1479},{"trials":1466,"activeCount":97},[],{"trials":1468,"activeCount":97},[],{"trials":1470,"activeCount":97},[],{"trials":1472,"activeCount":97},[1473],{"nctId":1364,"briefTitle":1365,"status":621,"phases":1474,"primaryCompletion":1358,"completion":1358,"start":1367,"enrollment":1368,"conditions":1475,"interventions":1476},[88],[33],[1371,1353,1335,1353],{"trials":1478,"activeCount":97},[],{"trials":1480,"activeCount":97},[],{"intervention":1482,"totalTrials":648,"cells":1483},"Umbilical Cord Mesenchymal Stem Cells",{"EARLY_PHASE1":1484,"PHASE1":1486,"PHASE2":1488,"PHASE3":1513,"PHASE4":1515,"NA":1517},{"trials":1485,"activeCount":97},[],{"trials":1487,"activeCount":97},[],{"trials":1489,"activeCount":97},[1490,1500,1507],{"nctId":1491,"briefTitle":1492,"status":181,"phases":1493,"primaryCompletion":195,"completion":195,"start":1494,"enrollment":1495,"conditions":1496,"interventions":1498},"NCT03521323","Intrathecal Transplantation of UC-MSC in Patients With Early Stage of Chronic Spinal Cord Injury",[87],"2019-09-01",66,[1497],"Spinal Cord Injuries",[1482,1499],"Placebos",{"nctId":1501,"briefTitle":1502,"status":181,"phases":1503,"primaryCompletion":195,"completion":195,"start":1494,"enrollment":1504,"conditions":1505,"interventions":1506},"NCT03521336","Intrathecal Transplantation of UC-MSC in Patients With Sub-Acute Spinal Cord Injury",[87],84,[471],[1482],{"nctId":1508,"briefTitle":1509,"status":181,"phases":1510,"primaryCompletion":195,"completion":195,"start":1494,"enrollment":332,"conditions":1511,"interventions":1512},"NCT03505034","Intrathecal Transplantation of UC-MSC in Patients With Late Stage of Chronic Spinal Cord Injury",[87],[1497],[1482],{"trials":1514,"activeCount":97},[],{"trials":1516,"activeCount":97},[],{"trials":1518,"activeCount":97},[],{"intervention":1520,"totalTrials":93,"cells":1521},"Camrelizumab + SOX",{"EARLY_PHASE1":1522,"PHASE1":1524,"PHASE2":1526,"PHASE3":1539,"PHASE4":1541,"NA":1543},{"trials":1523,"activeCount":97},[],{"trials":1525,"activeCount":97},[],{"trials":1527,"activeCount":97},[1528],{"nctId":1529,"briefTitle":1530,"status":181,"phases":1531,"primaryCompletion":1532,"completion":1533,"start":1534,"enrollment":1535,"conditions":1536,"interventions":1538},"NCT05545436","Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer",[87],"2022-12","2023-06","2022-09-20",34,[1537],"Locally Advanced Gastric Cancer",[1520],{"trials":1540,"activeCount":97},[],{"trials":1542,"activeCount":97},[],{"trials":1544,"activeCount":97},[],{"intervention":1546,"totalTrials":93,"cells":1547},"Mesenchymal Stem Cells",{"EARLY_PHASE1":1548,"PHASE1":1550,"PHASE2":1552,"PHASE3":1563,"PHASE4":1565,"NA":1567},{"trials":1549,"activeCount":97},[],{"trials":1551,"activeCount":97},[],{"trials":1553,"activeCount":97},[1554],{"nctId":1555,"briefTitle":1556,"status":181,"phases":1557,"primaryCompletion":1558,"completion":1559,"start":1560,"enrollment":391,"conditions":1561,"interventions":1562},"NCT02706132","Therapeutic Strategy and the Role of Mesenchymal Stromal Cells for ABO Incompatible Liver Transplantation",[86,87],"2016-12","2017-03","2014-02",[1011],[1546],{"trials":1564,"activeCount":97},[],{"trials":1566,"activeCount":97},[],{"trials":1568,"activeCount":97},[],{"intervention":611,"totalTrials":93,"cells":1570},{"EARLY_PHASE1":1571,"PHASE1":1573,"PHASE2":1575,"PHASE3":1581,"PHASE4":1583,"NA":1585},{"trials":1572,"activeCount":97},[],{"trials":1574,"activeCount":97},[],{"trials":1576,"activeCount":97},[1577],{"nctId":603,"briefTitle":604,"status":181,"phases":1578,"primaryCompletion":606,"completion":606,"start":607,"enrollment":608,"conditions":1579,"interventions":1580},[86,87],[14],[611,54,612,613,614,615],{"trials":1582,"activeCount":97},[],{"trials":1584,"activeCount":97},[],{"trials":1586,"activeCount":97},[],{"intervention":612,"totalTrials":93,"cells":1588},{"EARLY_PHASE1":1589,"PHASE1":1591,"PHASE2":1593,"PHASE3":1599,"PHASE4":1601,"NA":1603},{"trials":1590,"activeCount":97},[],{"trials":1592,"activeCount":97},[],{"trials":1594,"activeCount":97},[1595],{"nctId":603,"briefTitle":604,"status":181,"phases":1596,"primaryCompletion":606,"completion":606,"start":607,"enrollment":608,"conditions":1597,"interventions":1598},[86,87],[14],[611,54,612,613,614,615],{"trials":1600,"activeCount":97},[],{"trials":1602,"activeCount":97},[],{"trials":1604,"activeCount":97},[],{"intervention":613,"totalTrials":93,"cells":1606},{"EARLY_PHASE1":1607,"PHASE1":1609,"PHASE2":1611,"PHASE3":1617,"PHASE4":1619,"NA":1621},{"trials":1608,"activeCount":97},[],{"trials":1610,"activeCount":97},[],{"trials":1612,"activeCount":97},[1613],{"nctId":603,"briefTitle":604,"status":181,"phases":1614,"primaryCompletion":606,"completion":606,"start":607,"enrollment":608,"conditions":1615,"interventions":1616},[86,87],[14],[611,54,612,613,614,615],{"trials":1618,"activeCount":97},[],{"trials":1620,"activeCount":97},[],{"trials":1622,"activeCount":97},[],{"intervention":614,"totalTrials":93,"cells":1624},{"EARLY_PHASE1":1625,"PHASE1":1627,"PHASE2":1629,"PHASE3":1635,"PHASE4":1637,"NA":1639},{"trials":1626,"activeCount":97},[],{"trials":1628,"activeCount":97},[],{"trials":1630,"activeCount":97},[1631],{"nctId":603,"briefTitle":604,"status":181,"phases":1632,"primaryCompletion":606,"completion":606,"start":607,"enrollment":608,"conditions":1633,"interventions":1634},[86,87],[14],[611,54,612,613,614,615],{"trials":1636,"activeCount":97},[],{"trials":1638,"activeCount":97},[],{"trials":1640,"activeCount":97},[],{"intervention":615,"totalTrials":93,"cells":1642},{"EARLY_PHASE1":1643,"PHASE1":1645,"PHASE2":1647,"PHASE3":1653,"PHASE4":1655,"NA":1657},{"trials":1644,"activeCount":97},[],{"trials":1646,"activeCount":97},[],{"trials":1648,"activeCount":97},[1649],{"nctId":603,"briefTitle":604,"status":181,"phases":1650,"primaryCompletion":606,"completion":606,"start":607,"enrollment":608,"conditions":1651,"interventions":1652},[86,87],[14],[611,54,612,613,614,615],{"trials":1654,"activeCount":97},[],{"trials":1656,"activeCount":97},[],{"trials":1658,"activeCount":97},[],{"intervention":1499,"totalTrials":93,"cells":1660},{"EARLY_PHASE1":1661,"PHASE1":1663,"PHASE2":1665,"PHASE3":1671,"PHASE4":1673,"NA":1675},{"trials":1662,"activeCount":97},[],{"trials":1664,"activeCount":97},[],{"trials":1666,"activeCount":97},[1667],{"nctId":1491,"briefTitle":1492,"status":181,"phases":1668,"primaryCompletion":195,"completion":195,"start":1494,"enrollment":1495,"conditions":1669,"interventions":1670},[87],[1497],[1482,1499],{"trials":1672,"activeCount":97},[],{"trials":1674,"activeCount":97},[],{"trials":1676,"activeCount":97},[],{"intervention":1678,"totalTrials":93,"cells":1679},"HPDCs-T immune therapy",{"EARLY_PHASE1":1680,"PHASE1":1682,"PHASE2":1684,"PHASE3":1693,"PHASE4":1695,"NA":1697},{"trials":1681,"activeCount":97},[],{"trials":1683,"activeCount":97},[],{"trials":1685,"activeCount":97},[1686],{"nctId":1687,"briefTitle":1688,"status":621,"phases":1689,"primaryCompletion":897,"completion":897,"start":1690,"enrollment":1053,"conditions":1691,"interventions":1692},"NCT01935635","A Clinical Trial on HB-Vac Activated-DCs Combined With Peg-IFN or NAs in CHB",[86,87],"2015-01",[14],[1678],{"trials":1694,"activeCount":97},[],{"trials":1696,"activeCount":97},[],{"trials":1698,"activeCount":97},[],{"intervention":1700,"totalTrials":93,"cells":1701},"Neoadjuvant therapy with PD-L1 inhibitor",{"EARLY_PHASE1":1702,"PHASE1":1704,"PHASE2":1706,"PHASE3":1721,"PHASE4":1723,"NA":1725},{"trials":1703,"activeCount":97},[],{"trials":1705,"activeCount":97},[],{"trials":1707,"activeCount":97},[1708],{"nctId":1709,"briefTitle":1710,"status":181,"phases":1711,"primaryCompletion":1712,"completion":53,"start":1713,"enrollment":1714,"conditions":1715,"interventions":1720},"NCT05371197","Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR\u002FMSI-H Colorectal Cancer",[87],"2024-06-30","2022-05-05",26,[1716,1717,1718,1719],"Colorectal Cancer","Mismatch Repair-deficient (dMMR)","Microsatellite Instability-high (MSI-H)","Neoadjuvant Therapy",[1700],{"trials":1722,"activeCount":97},[],{"trials":1724,"activeCount":97},[],{"trials":1726,"activeCount":97},[],{"intervention":1728,"totalTrials":93,"cells":1729},"Conventional plus BM-MSC treatment",{"EARLY_PHASE1":1730,"PHASE1":1732,"PHASE2":1734,"PHASE3":1747,"PHASE4":1749,"NA":1751},{"trials":1731,"activeCount":97},[],{"trials":1733,"activeCount":97},[],{"trials":1735,"activeCount":97},[1736],{"nctId":1737,"briefTitle":1738,"status":181,"phases":1739,"primaryCompletion":184,"completion":1740,"start":1741,"enrollment":1742,"conditions":1743,"interventions":1744},"NCT01844063","Safety and Efficacy of Diverse Mesenchymal Stem Cells Transplantation for Liver Failure",[86,87],"2019-01","2013-07",210,[31],[1728,1745,1746],"Conventional plus UC-MSC treatment","Conventional treatment",{"trials":1748,"activeCount":97},[],{"trials":1750,"activeCount":97},[],{"trials":1752,"activeCount":97},[],{"intervention":1745,"totalTrials":93,"cells":1754},{"EARLY_PHASE1":1755,"PHASE1":1757,"PHASE2":1759,"PHASE3":1765,"PHASE4":1767,"NA":1769},{"trials":1756,"activeCount":97},[],{"trials":1758,"activeCount":97},[],{"trials":1760,"activeCount":97},[1761],{"nctId":1737,"briefTitle":1738,"status":181,"phases":1762,"primaryCompletion":184,"completion":1740,"start":1741,"enrollment":1742,"conditions":1763,"interventions":1764},[86,87],[31],[1728,1745,1746],{"trials":1766,"activeCount":97},[],{"trials":1768,"activeCount":97},[],{"trials":1770,"activeCount":97},[],{"intervention":1746,"totalTrials":93,"cells":1772},{"EARLY_PHASE1":1773,"PHASE1":1775,"PHASE2":1777,"PHASE3":1783,"PHASE4":1785,"NA":1787},{"trials":1774,"activeCount":97},[],{"trials":1776,"activeCount":97},[],{"trials":1778,"activeCount":97},[1779],{"nctId":1737,"briefTitle":1738,"status":181,"phases":1780,"primaryCompletion":184,"completion":1740,"start":1741,"enrollment":1742,"conditions":1781,"interventions":1782},[86,87],[31],[1728,1745,1746],{"trials":1784,"activeCount":97},[],{"trials":1786,"activeCount":97},[],{"trials":1788,"activeCount":97},[],{"intervention":1790,"totalTrials":93,"cells":1791},"Indocyanine Green",{"EARLY_PHASE1":1792,"PHASE1":1794,"PHASE2":1804,"PHASE3":1806,"PHASE4":1808,"NA":1810},{"trials":1793,"activeCount":97},[],{"trials":1795,"activeCount":97},[1796],{"nctId":1797,"briefTitle":1798,"status":181,"phases":1799,"primaryCompletion":183,"start":208,"enrollment":1800,"conditions":1801,"interventions":1803},"NCT02840617","ICG-based Fluorescence Imaging in Localization of Prostate Cancer and Metastatic Lymph Nodes",[86],50,[1802],"Prostate Cancer",[1790],{"trials":1805,"activeCount":97},[],{"trials":1807,"activeCount":97},[],{"trials":1809,"activeCount":97},[],{"trials":1811,"activeCount":97},[],{"intervention":1813,"totalTrials":93,"cells":1814},"Camrelizumab treatment",{"EARLY_PHASE1":1815,"PHASE1":1817,"PHASE2":1827,"PHASE3":1829,"PHASE4":1831,"NA":1833},{"trials":1816,"activeCount":97},[],{"trials":1818,"activeCount":97},[1819],{"nctId":1820,"briefTitle":1821,"status":181,"phases":1822,"primaryCompletion":1823,"completion":936,"start":1824,"enrollment":494,"conditions":1825,"interventions":1826},"NCT04564313","Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation",[86],"2022-09","2020-09-21",[23,1011],[1813],{"trials":1828,"activeCount":97},[],{"trials":1830,"activeCount":97},[],{"trials":1832,"activeCount":97},[],{"trials":1834,"activeCount":97},[],{"intervention":1836,"totalTrials":93,"cells":1837},"Low Dose NK cells ×4 times",{"EARLY_PHASE1":1838,"PHASE1":1840,"PHASE2":1853,"PHASE3":1855,"PHASE4":1857,"NA":1859},{"trials":1839,"activeCount":97},[],{"trials":1841,"activeCount":97},[1842],{"nctId":1843,"briefTitle":1844,"status":181,"phases":1845,"primaryCompletion":1846,"completion":1846,"start":1847,"enrollment":1848,"conditions":1849,"interventions":1850},"NCT02399735","Safety Study of NK Cells From Sibship to Treat the Recurrence of HCC After Liver Transplantation",[86],"2018-06","2014-10",18,[23],[1836,1851,1852],"Normal Dose NK cells ×4 times","Normal Dose NK cells ×8 times",{"trials":1854,"activeCount":97},[],{"trials":1856,"activeCount":97},[],{"trials":1858,"activeCount":97},[],{"trials":1860,"activeCount":97},[],{"intervention":1851,"totalTrials":93,"cells":1862},{"EARLY_PHASE1":1863,"PHASE1":1865,"PHASE2":1871,"PHASE3":1873,"PHASE4":1875,"NA":1877},{"trials":1864,"activeCount":97},[],{"trials":1866,"activeCount":97},[1867],{"nctId":1843,"briefTitle":1844,"status":181,"phases":1868,"primaryCompletion":1846,"completion":1846,"start":1847,"enrollment":1848,"conditions":1869,"interventions":1870},[86],[23],[1836,1851,1852],{"trials":1872,"activeCount":97},[],{"trials":1874,"activeCount":97},[],{"trials":1876,"activeCount":97},[],{"trials":1878,"activeCount":97},[],{"intervention":1852,"totalTrials":93,"cells":1880},{"EARLY_PHASE1":1881,"PHASE1":1883,"PHASE2":1889,"PHASE3":1891,"PHASE4":1893,"NA":1895},{"trials":1882,"activeCount":97},[],{"trials":1884,"activeCount":97},[1885],{"nctId":1843,"briefTitle":1844,"status":181,"phases":1886,"primaryCompletion":1846,"completion":1846,"start":1847,"enrollment":1848,"conditions":1887,"interventions":1888},[86],[23],[1836,1851,1852],{"trials":1890,"activeCount":97},[],{"trials":1892,"activeCount":97},[],{"trials":1894,"activeCount":97},[],{"trials":1896,"activeCount":97},[],{"intervention":1898,"totalTrials":93,"cells":1899},"MSC-EV",{"EARLY_PHASE1":1900,"PHASE1":1902,"PHASE2":1913,"PHASE3":1915,"PHASE4":1917,"NA":1919},{"trials":1901,"activeCount":97},[],{"trials":1903,"activeCount":97},[1904],{"nctId":1905,"briefTitle":1906,"status":364,"phases":1907,"primaryCompletion":366,"completion":1908,"start":1909,"enrollment":97,"conditions":1910,"interventions":1912},"NCT05881668","MSC-EV in Acute-on-Chronic Liver Failure After Liver Transplantation",[86],"2025-04-30","2023-09-30",[1911],"Liver Failure, Acute on Chronic",[1898],{"trials":1914,"activeCount":97},[],{"trials":1916,"activeCount":97},[],{"trials":1918,"activeCount":97},[],{"trials":1920,"activeCount":97},[],{"intervention":943,"totalTrials":93,"cells":1922},{"EARLY_PHASE1":1923,"PHASE1":1929,"PHASE2":1931,"PHASE3":1933,"PHASE4":1935,"NA":1937},{"trials":1924,"activeCount":97},[1925],{"nctId":933,"briefTitle":934,"status":181,"phases":1926,"primaryCompletion":936,"completion":937,"start":938,"enrollment":939,"conditions":1927,"interventions":1928},[85],[941],[928,943,944],{"trials":1930,"activeCount":97},[],{"trials":1932,"activeCount":97},[],{"trials":1934,"activeCount":97},[],{"trials":1936,"activeCount":97},[],{"trials":1938,"activeCount":97},[],{"intervention":944,"totalTrials":93,"cells":1940},{"EARLY_PHASE1":1941,"PHASE1":1947,"PHASE2":1949,"PHASE3":1951,"PHASE4":1953,"NA":1955},{"trials":1942,"activeCount":97},[1943],{"nctId":933,"briefTitle":934,"status":181,"phases":1944,"primaryCompletion":936,"completion":937,"start":938,"enrollment":939,"conditions":1945,"interventions":1946},[85],[941],[928,943,944],{"trials":1948,"activeCount":97},[],{"trials":1950,"activeCount":97},[],{"trials":1952,"activeCount":97},[],{"trials":1954,"activeCount":97},[],{"trials":1956,"activeCount":97},[],{"intervention":1958,"totalTrials":93,"cells":1959},"Tenofovir Alafenamide 25 MG",{"EARLY_PHASE1":1960,"PHASE1":1973,"PHASE2":1975,"PHASE3":1977,"PHASE4":1979,"NA":1981},{"trials":1961,"activeCount":97},[1962],{"nctId":1963,"briefTitle":1964,"status":181,"phases":1965,"primaryCompletion":1966,"completion":1967,"start":1968,"enrollment":1800,"conditions":1969,"interventions":1972},"NCT04507607","Efficacy and Safety of TAF in Pregnant Women With Chronic Hepatitis B Infection",[85],"2020-12-30","2021-06-30","2020-08-01",[14,1970,1971],"Mother-to-child Block","Antiviral Treatment",[1958],{"trials":1974,"activeCount":97},[],{"trials":1976,"activeCount":97},[],{"trials":1978,"activeCount":97},[],{"trials":1980,"activeCount":97},[],{"trials":1982,"activeCount":97},[],{"intervention":202,"totalTrials":220,"cells":1984},{"EARLY_PHASE1":1985,"PHASE1":1987,"PHASE2":1989,"PHASE3":1991,"PHASE4":1993,"NA":1995},{"trials":1986,"activeCount":97},[],{"trials":1988,"activeCount":97},[],{"trials":1990,"activeCount":97},[],{"trials":1992,"activeCount":97},[],{"trials":1994,"activeCount":97},[],{"trials":1996,"activeCount":97},[1997,2001],{"nctId":191,"briefTitle":192,"status":181,"phases":1998,"primaryCompletion":194,"completion":195,"start":196,"enrollment":197,"conditions":1999,"interventions":2000},[90],[20,199],[201,202,162],{"nctId":213,"briefTitle":214,"status":181,"phases":2002,"primaryCompletion":216,"completion":195,"start":196,"enrollment":185,"conditions":2003,"interventions":2004},[90],[20,199],[201,202,162],{"intervention":2006,"totalTrials":220,"cells":2007},"Ledipasvir-Sofosbuvir",{"EARLY_PHASE1":2008,"PHASE1":2020,"PHASE2":2022,"PHASE3":2024,"PHASE4":2026,"NA":2028},{"trials":2009,"activeCount":97},[2010],{"nctId":2011,"briefTitle":2012,"status":621,"phases":2013,"primaryCompletion":2014,"completion":2014,"start":2015,"enrollment":2016,"conditions":2017,"interventions":2018},"NCT03188276","The Relationship Between MDSCs and NK Cells Activity of CHC Patient Treated by DAAs",[85],"2017-05-01","2016-02-01",52,[33],[2006,2019],"Daclatasvir-Sofosbuvir",{"trials":2021,"activeCount":97},[],{"trials":2023,"activeCount":97},[],{"trials":2025,"activeCount":97},[],{"trials":2027,"activeCount":97},[],{"trials":2029,"activeCount":97},[2030],{"nctId":2031,"briefTitle":2032,"status":621,"phases":2033,"primaryCompletion":2034,"completion":2034,"start":2035,"enrollment":2036,"conditions":2037,"interventions":2039},"NCT03063723","Dynamic Changes of Monocytes and NK Cells of CHC Patient Treated by DAAs",[],"2016-12-01","2016-01-01",25,[2038],"Chronic Hepatitis C (Disorder)",[2006,2019],{"intervention":2019,"totalTrials":220,"cells":2041},{"EARLY_PHASE1":2042,"PHASE1":2048,"PHASE2":2050,"PHASE3":2052,"PHASE4":2054,"NA":2056},{"trials":2043,"activeCount":97},[2044],{"nctId":2011,"briefTitle":2012,"status":621,"phases":2045,"primaryCompletion":2014,"completion":2014,"start":2015,"enrollment":2016,"conditions":2046,"interventions":2047},[85],[33],[2006,2019],{"trials":2049,"activeCount":97},[],{"trials":2051,"activeCount":97},[],{"trials":2053,"activeCount":97},[],{"trials":2055,"activeCount":97},[],{"trials":2057,"activeCount":97},[2058],{"nctId":2031,"briefTitle":2032,"status":621,"phases":2059,"primaryCompletion":2034,"completion":2034,"start":2035,"enrollment":2036,"conditions":2060,"interventions":2061},[],[2038],[2006,2019],{"intervention":561,"totalTrials":93,"cells":2063},{"EARLY_PHASE1":2064,"PHASE1":2066,"PHASE2":2068,"PHASE3":2070,"PHASE4":2072,"NA":2074},{"trials":2065,"activeCount":97},[],{"trials":2067,"activeCount":97},[],{"trials":2069,"activeCount":97},[],{"trials":2071,"activeCount":97},[],{"trials":2073,"activeCount":97},[],{"trials":2075,"activeCount":97},[2076],{"nctId":552,"briefTitle":553,"status":181,"phases":2077,"primaryCompletion":555,"completion":556,"start":557,"enrollment":558,"conditions":2078,"interventions":2079},[90],[20,199],[201,561],{"intervention":2081,"totalTrials":93,"cells":2082},"enteric-coated mycophenolate",{"EARLY_PHASE1":2083,"PHASE1":2085,"PHASE2":2087,"PHASE3":2089,"PHASE4":2091,"NA":2093},{"trials":2084,"activeCount":97},[],{"trials":2086,"activeCount":97},[],{"trials":2088,"activeCount":97},[],{"trials":2090,"activeCount":97},[],{"trials":2092,"activeCount":97},[],{"trials":2094,"activeCount":97},[2095],{"nctId":2096,"briefTitle":2097,"status":181,"phases":2098,"primaryCompletion":2099,"completion":1909,"start":2100,"enrollment":2101,"conditions":2102,"interventions":2105},"NCT05707520","Long-term Benefit of MPA in Liver Transplantation",[],"2023-06-30","2022-12-04",500,[2103,2104],"Liver Transplant Rejection","Immunosuppressant Adverse Reaction",[2081,2106],"None MPA",{"intervention":2106,"totalTrials":93,"cells":2108},{"EARLY_PHASE1":2109,"PHASE1":2111,"PHASE2":2113,"PHASE3":2115,"PHASE4":2117,"NA":2119},{"trials":2110,"activeCount":97},[],{"trials":2112,"activeCount":97},[],{"trials":2114,"activeCount":97},[],{"trials":2116,"activeCount":97},[],{"trials":2118,"activeCount":97},[],{"trials":2120,"activeCount":97},[2121],{"nctId":2096,"briefTitle":2097,"status":181,"phases":2122,"primaryCompletion":2099,"completion":1909,"start":2100,"enrollment":2101,"conditions":2123,"interventions":2124},[],[2103,2104],[2081,2106],{"intervention":2126,"totalTrials":93,"cells":2127},"DAAs",{"EARLY_PHASE1":2128,"PHASE1":2130,"PHASE2":2132,"PHASE3":2134,"PHASE4":2136,"NA":2138},{"trials":2129,"activeCount":97},[],{"trials":2131,"activeCount":97},[],{"trials":2133,"activeCount":97},[],{"trials":2135,"activeCount":97},[],{"trials":2137,"activeCount":97},[],{"trials":2139,"activeCount":97},[2140],{"nctId":2141,"briefTitle":2142,"status":181,"phases":2143,"primaryCompletion":2144,"completion":2145,"start":2146,"enrollment":2147,"conditions":2148,"interventions":2149},"NCT03887637","Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C)",[],"2019-08-30","2019-09-30","2019-03-30",180,[33],[2126],{"intervention":2151,"totalTrials":93,"cells":2152},"Probiotic Blend Oral",{"EARLY_PHASE1":2153,"PHASE1":2155,"PHASE2":2157,"PHASE3":2159,"PHASE4":2161,"NA":2163},{"trials":2154,"activeCount":97},[],{"trials":2156,"activeCount":97},[],{"trials":2158,"activeCount":97},[],{"trials":2160,"activeCount":97},[],{"trials":2162,"activeCount":97},[],{"trials":2164,"activeCount":97},[2165],{"nctId":2166,"briefTitle":2167,"status":621,"phases":2168,"primaryCompletion":195,"completion":195,"start":2169,"enrollment":354,"conditions":2170,"interventions":2172},"NCT06241222","Origin of the Neonatal Gut Microbiota and Probiotic Intervention",[90],"2018-01-01",[2171],"Microbiota",[2151],{"intervention":2174,"totalTrials":93,"cells":2175},"Neomycin,metronidazole",{"EARLY_PHASE1":2176,"PHASE1":2178,"PHASE2":2180,"PHASE3":2182,"PHASE4":2184,"NA":2186},{"trials":2177,"activeCount":97},[],{"trials":2179,"activeCount":97},[],{"trials":2181,"activeCount":97},[],{"trials":2183,"activeCount":97},[],{"trials":2185,"activeCount":97},[],{"trials":2187,"activeCount":97},[2188],{"nctId":2189,"briefTitle":2190,"status":621,"phases":2191,"primaryCompletion":2192,"completion":2193,"start":2194,"enrollment":2195,"conditions":2196,"interventions":2201},"NCT03856671","Prophylatic Effect Preoperative Antibiotics With Mechanical Bowel Preparation in SSIs",[90],"2022-12-30","2023-03-31","2019-01-17",309,[2197,2198,2199,2200,1716],"Surgical Site Infection","Postoperative Complications","Bowel Preparation","Oral Antibiotics",[2174],{"intervention":706,"totalTrials":93,"cells":2203},{"EARLY_PHASE1":2204,"PHASE1":2206,"PHASE2":2208,"PHASE3":2210,"PHASE4":2212,"NA":2214},{"trials":2205,"activeCount":97},[],{"trials":2207,"activeCount":97},[],{"trials":2209,"activeCount":97},[],{"trials":2211,"activeCount":97},[],{"trials":2213,"activeCount":97},[],{"trials":2215,"activeCount":97},[2216],{"nctId":697,"briefTitle":698,"status":181,"phases":2217,"primaryCompletion":194,"completion":700,"start":701,"enrollment":692,"conditions":2218,"interventions":2219},[90],[28,703],[705,706],{"intervention":2221,"totalTrials":93,"cells":2222},"TDF",{"EARLY_PHASE1":2223,"PHASE1":2225,"PHASE2":2227,"PHASE3":2229,"PHASE4":2231,"NA":2233},{"trials":2224,"activeCount":97},[],{"trials":2226,"activeCount":97},[],{"trials":2228,"activeCount":97},[],{"trials":2230,"activeCount":97},[],{"trials":2232,"activeCount":97},[],{"trials":2234,"activeCount":97},[2235],{"nctId":2236,"briefTitle":2237,"status":181,"phases":2238,"primaryCompletion":2239,"completion":2192,"start":2240,"enrollment":692,"conditions":2241,"interventions":2242},"NCT04650828","TDF Combined With LDT for the Treatment of HBeAg-positive Hepatitis B Patients With Poor Response to TDF for 12 Months",[],"2022-11-30","2020-12-01",[14],[2221,2243],"Tenofovir Disoproxil Fumarate 300 MG",{"intervention":2243,"totalTrials":93,"cells":2245},{"EARLY_PHASE1":2246,"PHASE1":2248,"PHASE2":2250,"PHASE3":2252,"PHASE4":2254,"NA":2256},{"trials":2247,"activeCount":97},[],{"trials":2249,"activeCount":97},[],{"trials":2251,"activeCount":97},[],{"trials":2253,"activeCount":97},[],{"trials":2255,"activeCount":97},[],{"trials":2257,"activeCount":97},[2258],{"nctId":2236,"briefTitle":2237,"status":181,"phases":2259,"primaryCompletion":2239,"completion":2192,"start":2240,"enrollment":692,"conditions":2260,"interventions":2261},[],[14],[2221,2243],{"intervention":2263,"totalTrials":93,"cells":2264},"Oral antibiotics",{"EARLY_PHASE1":2265,"PHASE1":2267,"PHASE2":2269,"PHASE3":2271,"PHASE4":2273,"NA":2275},{"trials":2266,"activeCount":97},[],{"trials":2268,"activeCount":97},[],{"trials":2270,"activeCount":97},[],{"trials":2272,"activeCount":97},[],{"trials":2274,"activeCount":97},[],{"trials":2276,"activeCount":97},[2277],{"nctId":2278,"briefTitle":2279,"status":621,"phases":2280,"primaryCompletion":1077,"completion":2281,"start":1285,"enrollment":2282,"conditions":2283,"interventions":2284},"NCT04258098","Prophylatic Effect Preoperative Antibiotics With Mechanical Bowel Preparation in SSIs: A Propensity Analysis",[],"2019-05-12",806,[2197,1716],[2263],{"intervention":2286,"totalTrials":93,"cells":2287},"Interferon Alfa 2a",{"EARLY_PHASE1":2288,"PHASE1":2290,"PHASE2":2292,"PHASE3":2294,"PHASE4":2296,"NA":2298},{"trials":2289,"activeCount":97},[],{"trials":2291,"activeCount":97},[],{"trials":2293,"activeCount":97},[],{"trials":2295,"activeCount":97},[],{"trials":2297,"activeCount":97},[],{"trials":2299,"activeCount":97},[2300],{"nctId":2301,"briefTitle":2302,"status":181,"phases":2303,"primaryCompletion":2304,"completion":195,"start":2305,"enrollment":185,"conditions":2306,"interventions":2308},"NCT03733652","Optimal Treatment for Poor Efficacy of Entecavir in Chronic Hepatitis B Patients",[90],"2021-09-30","2018-11-15",[28,2307],"Efficacy, Self",[2286],{"intervention":2310,"totalTrials":93,"cells":2311},"Epclusa",{"EARLY_PHASE1":2312,"PHASE1":2314,"PHASE2":2316,"PHASE3":2318,"PHASE4":2320,"NA":2322},{"trials":2313,"activeCount":97},[],{"trials":2315,"activeCount":97},[],{"trials":2317,"activeCount":97},[],{"trials":2319,"activeCount":97},[],{"trials":2321,"activeCount":97},[],{"trials":2323,"activeCount":97},[2324],{"nctId":2325,"briefTitle":2326,"status":181,"phases":2327,"primaryCompletion":2328,"completion":2329,"start":2330,"enrollment":235,"conditions":2331,"interventions":2333},"NCT04948801","SOF\u002FVEL±RBV: Efficacy and Safety in GT 3 and 6 HCV Patients",[],"2021-12-01","2021-12-30","2018-12-08",[2332],"Hepatitis C",[2310]]